Detailed information for compound 350739
Basic information
Technical information
- TDR Targets ID: 350739
- Name: 2-(1-butyl-5,8-dichloro-3,4-dihydro-[1]benzot hiolo[2,3-c]pyran-1-yl)acetic acid
- MW: 373.294 | Formula: C17H18Cl2O3S
-
H donors: 1
H acceptors: 2
LogP: 5.06
Rotable bonds: 5
Rule of 5 violations (Lipinski): 1 - SMILES: CCCCC1(OCCc2c1sc1c2c(Cl)ccc1Cl)CC(=O)O
- InChi: 1S/C17H18Cl2O3S/c1-2-3-7-17(9-13(20)21)16-10(6-8-22-17)14-11(18)4-5-12(19)15(14)23-16/h4-5H,2-3,6-9H2,1H3,(H,20,21)
- InChiKey: GKDYSNBFODVCMO-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 2-(1-butyl-5,8-dichloro-3,4-dihydrobenzothiopheno[2,3-c]pyran-1-yl)acetic acid
- 2-(1-butyl-5,8-dichloro-3,4-dihydro-[1]benzothiolo[2,3-c]pyran-1-yl)ethanoic acid
Targets
Known targets for this compound
| Species | Target name | Source | Bibliographic reference |
|---|---|---|---|
| Hepatitis C virus | Hepatitis C virus NS5B RNA-dependent RNA polymerase | Starlite/ChEMBL | References |
Predicted pathogen targets for this compound
By orthology
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Mycobacterium leprae | DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE | 0.0112 | 0.1234 | 0.5 |
| Toxoplasma gondii | thioredoxin reductase | 0.0323 | 1 | 1 |
| Brugia malayi | dihydrolipoyl dehydrogenase, mitochondrial precursor, putative | 0.0112 | 0.1234 | 0.1234 |
| Loa Loa (eye worm) | glutathione reductase | 0.0323 | 1 | 0.5 |
| Mycobacterium tuberculosis | NADPH-dependent mycothiol reductase Mtr | 0.0323 | 1 | 1 |
| Mycobacterium ulcerans | dihydrolipoamide dehydrogenase, LpdB | 0.0112 | 0.1234 | 0.5 |
| Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0112 | 0.1234 | 0.5 |
| Trichomonas vaginalis | mercuric reductase, putative | 0.0112 | 0.1234 | 0.5 |
| Trichomonas vaginalis | glutathione reductase, putative | 0.0112 | 0.1234 | 0.5 |
| Plasmodium vivax | glutathione reductase, putative | 0.0323 | 1 | 1 |
| Mycobacterium ulcerans | flavoprotein disulfide reductase | 0.0112 | 0.1234 | 0.5 |
| Trypanosoma brucei | trypanothione reductase | 0.0323 | 1 | 1 |
| Mycobacterium ulcerans | dihydrolipoamide dehydrogenase | 0.0112 | 0.1234 | 0.5 |
| Brugia malayi | Thioredoxin reductase | 0.0323 | 1 | 1 |
| Plasmodium falciparum | thioredoxin reductase | 0.0323 | 1 | 1 |
| Plasmodium falciparum | glutathione reductase | 0.0323 | 1 | 1 |
| Wolbachia endosymbiont of Brugia malayi | dihydrolipoamide dehydrogenase E3 component | 0.0112 | 0.1234 | 0.5 |
| Treponema pallidum | NADH oxidase | 0.0112 | 0.1234 | 0.5 |
| Loa Loa (eye worm) | thioredoxin reductase | 0.0323 | 1 | 0.5 |
| Echinococcus multilocularis | thioredoxin glutathione reductase | 0.0323 | 1 | 1 |
| Plasmodium vivax | thioredoxin reductase, putative | 0.0323 | 1 | 1 |
| Leishmania major | trypanothione reductase | 0.0323 | 1 | 1 |
| Chlamydia trachomatis | dihydrolipoyl dehydrogenase | 0.0112 | 0.1234 | 0.5 |
| Trypanosoma cruzi | trypanothione reductase, putative | 0.0323 | 1 | 1 |
| Echinococcus granulosus | thioredoxin glutathione reductase | 0.0323 | 1 | 1 |
| Giardia lamblia | NADH oxidase lateral transfer candidate | 0.0112 | 0.1234 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| IC50 (binding) | = 0.75 uM | Displacement of [alpha-32P]GTP from recombinant HCV NS5B RNA dependent RNA polymerase | ChEMBL. | 16274990 |
| IC50 (binding) | = 0.75 uM | Displacement of [alpha-32P]GTP from recombinant HCV NS5B RNA dependent RNA polymerase | ChEMBL. | 16274990 |
Phenotypes
Whole-cell/tissue/organism interactions
We have no records of whole-cell/tissue assays done with this compound
What does this mean?
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- PubChem: 11581550
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.